VistaGen Therapeutics (NASDAQ: VTGN) Featured Research Report

12 A EGIS C APITAL C ORP. Fig. 7. PH10 Phase 2A results Source: VistaGen, Phar Med Res VistaGen Therapeutics, Inc. October 8, 2020